Latest news and press releases about CG Oncology Inc. (CGON): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in...
Price
| Price | $74.12 |
| Market Cap | $6.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.32 |
| EV / EBITDA | -28.74 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -25.20% |
| Return on Invested Capital | -24.30% |
| Return on Assets | -20.67% |
| Gross Margin | -82.69% |
| Operating Margin | -4056.18% |
| Net Margin | -3602.68% |
Related companies: AAPG · APGE · CELC · CNTA · IRON · LEGN · RARE
Explore sector: Healthcare · Biotechnology
More sections of CGON: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks